Navigation Links
Pneumonia Drug Promising Against Form of Muscular Dystrophy
Date:11/12/2009

In studies with mice, pentamidine combats genetic defects that lead to myotonic dystrophy

THURSDAY, Nov. 12 (HealthDay News) -- Researchers report that a drug used to treat pneumonia might serve as an effective treatment against a type of muscular dystrophy.

They tested the drug pentamidine in mice and found that it appears to combat genetic defects that lead to type 1 myotonic dystrophy, one of nine types of muscular dystrophy. The muscle-wasting condition is also known as DM1 and Steinart's disease.

The levels used in mice would be poisonous in humans, but University of Oregon chemist J. Andrew Berglund, whose lab tested the drug, said it could be modified.

Pentamidine is approved to treat several conditions, including a severe type of pneumonia in people with compromised immune systems, some yeast infections and sleeping sickness.

"Pentamidine is an exciting lead compound because it is relatively easy to chemically modify, and hopefully one of these modified compounds could lead to a safe, long-term treatment for DM1 in the future," said Berglund.

The study, funded in part by the U.S. National Institutes of Health and the Muscular Dystrophy Association, was published in the Nov. 3 issue of Proceedings of the National Academy of Sciences.

More information

Learn more about muscular dystrophy from the National Institutes of Health.



--Randy Dotinga



SOURCE: University of Oregon, press release, Nov. 6, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Page: 1

Related medicine news :

1. Zinc Helps Elderly Ward Off Pneumonia
2. Heart attacks/pneumonia falls short of national goals
3. Emergency Care for Heart Attacks, Pneumonia Fails to Meet Goals
4. Cethromycin achieves all endpoints in second pivotal Phase III Trial for treatment for pneumonia
5. Pneumonia Vaccine Is Keeping Kids Healthier
6. Treating Childhood Pneumonia at Home Could Save Lives in Developing Countries
7. Childrens Hospital scientists identify possible target for prevention and treatment of pneumonia
8. Community-Based Staph Pneumonia More Common Than Thought
9. TB Drug Treatment Can Lead to Severe Pneumonia
10. Antipsychotic drugs increase risk of developing pneumonia in elderly
11. Bayer/Schering-Plough/Shionogis Avelox Has Advantages Over Levofloxacin in the Treatment of Community-Acquired Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/13/2017)... ... , ... “America On The Brink”: the Christian history of the United States ... creation of published author, William Nowers. Captain Nowers and his wife, Millie, have ... thirty years in the Navy. Following his career as a naval aviator and ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... 4, 2017 OBP Medical , ... medical devices, today announced regulatory approval from ... (or Agência Nacional de Vigilância Sanitária (ANVISA)) to ... surgical retractor with integrated LED light source and ... and exposure of a tissue pocket or cavity ...
(Date:10/2/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... of 2017 on Tuesday, October 24, 2017. Lilly will ... the investment community and media to further detail the ... begin at 9 a.m. Eastern time. Investors, media and ... the conference call through a link that will be ...
(Date:10/2/2017)... Halo Labs announces the European launch of their new low volume, ... 2017 in Cambridge, U.K on October 4th. ... samples with unprecedented speed and sensitivity while using far less sample ... ... system ...
Breaking Medicine Technology: